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Abstract
Background: Advances in endovascular technology led to an alternative treatment option for TASC II D (TransAtlantic
Inter-Society Consensus II class D) lesions. This study was aimed to evaluate the outcomes of endovascular treatment
for TASC II D femoropopliteal lesions.
Methods: Endovascular intervention with bare nitinol stent implantation was performed on 58 limbs (53 patients)
with TASC II D femoropopliteal lesions from January 2011 to March 2013. Kaplan-Meier curves of primary patency,
assisted patency and second patency were performed. Predictive factors of re-stenosis/occlusion were evaluated
by univariate methods.
Results: Total 53 patients with mean age of 74.2 ± 8.2 (range, 58.0–91.0 years) and mean lesion length of 314.8 ±
64.3 mm (188.2–400.4 mm) were enrolled. The mean follow-up time was 12.2 ± 6.1 months (5–38 months).
Revascularization was successfully on 95 % lesions by bare nitinol stent implantation. Primary patency rates at
1, 2 and 3 years were 63 %, 12 % and 12 %, respectively. Assisted primary patency rates at 1, 2 and 3 years were
77 %, 31 % and 31 %, respectively. Secondary patency rates at 1, 2 and 3 years were 96 %, 63 % and 63 %. During
one-year follow-up, no major amputation was occurred. Univariate analysis revealed that number of run-off vessels was
a potential predictor of re-stenosis/occlusion.
Conclusion: Endovascular treatment of TASC II D femoropopliteal artery occlusion has a high technical success rate
with acceptable one-year patency rate. The long-term outcomes are poor, but endovascular intervention could be a
good alternative for patients unsuitable for surgical bypass.
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Background
Peripheral artery disease (PAD) is a common circulatory
problem, which refers to the obstruction of blood flow
in the arteries exclusive of the coronary and cerebral
vessels. Patients with PAD may suffer from claudication,
ischemic rest pain, ischemic ulcerations and limb loss
which consequently results in a poor quality of life and a
high rate of depression. Treatment of PAD comprises
conservative management for symptoms of claudication,
such as risk factor modification, exercise therapy and an-
tithrombotic therapy, and catheter-based or surgical
revascularization for patients with critical limb ischemia
(CLI) [1–3]. Endovascular treatment is an attractive
alternative to open surgical procedures for PAD due to
the less procedural risk resulted by it. The recent Trans-
Atlantic InterSociety Consensus Document on Manage-
ment of Peripheral Arterial Disease (TASC) advocates
endovascular treatment for TASC A and B lesions in
femoral artery [4]. Moreover, unlike the TASC I Consen-
sus, the TASC II update allows for more flexibility in
TASC C lesions with respect to primary treatment with
endovascular therapy based on patient factors. As for
TASC D lesions, vein bypass remains to be the standard
option for TASC D lesions, but it may be inappropriate
for patients with severe medical comorbidities or lack of
suitable vein conduits [5, 6].
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With continuing advances in techniques and facilities,
endovascular treatment enabled complex, long-segment
occlusions to be revascularized successfully. Some reports
showed good technical success rate and low perioperative
complications in long SFA (superficial femoral artery)
lesions [7, 8]. But, the follow-up time of these studies was
short. Moreover, until now, few articles are focusing on
the outcomes of primary stent-intervention on TASC-D
lesions. Although primary balloon angioplasty with se-
lective stenting is used in less severe lesions [9], pri-
mary stenting is still the most common treatment for
long occlusions in the SFA. So, here we reported our
experience on endovascular therapy with stenting for
ASC II D femoropopliteal lesions with a long follow-up
time (mean, 12.2 ± 6.1 months; range, 5 to 38 months).
Methods
Patients
From January 2011 to March 2013, 53 patients with 58
limbs involving TASC II D femoropopliteal lesions were
retrospectively enrolled in this study. Of these limbs, 30
were lifestyle-limiting claudication (Rutherford category
2/3), 17 were rest pain (Rutheford category 4), and 11
were gangrene (Rutherford category 5). Patients who
had experienced any endovascular or bypass procedures
prior to this study and patients with occlusion of iliac or
common femoral artery were excluded.
Procedures
Endovascular interventions were performed under local
anesthesia by our vascular surgeons. Access to the culprit
lesion was achieved by way of a crossover approach using a
dedicated 6 F-long sheath (45 cm) (COOK, USA). Ante-
grade approach and subintimal recanalization were usually
used to gain access to the distal true lumen. If necessary,
SAFARI techniques (subintimal arterial flossing with
antegrade-retrograde intervention) were performed to im-
prove technical success. Retrograde access was gained in
the distal target artery (popliteal, anterior tibial, peroneal,
or posterior tibial) and a retrograde subintimal channel
was created. A hydrophilic 0.035-inch guide wire was used
to connect the retrograde and antegrade subintimal chan-
nels simultaneously to create a “flossing” guide wire. Predi-
lation with small balloon catheter was carried out. Stents
were routinely deployed and lesions were treated with as
few stents as possible. Adjacent stents were overlapped by
1 cm. Three types of nitinol self-expanding stents: Protégé
Everflex (ev3 Inc., USA), Lifestent (Bard Inc, USA), and
SMART Control (Cordis Corporation) were used accord-
ing to operator discretion. Stents were routinely post-
dilated to ensure optimal extension and apposition. The
balloon dimension was chosen 1 mm narrower than the
vessel diameter to reduce medial damage, and the balloon
length should not exceed that of the stent [10].
Clopidogrel was administered 75 mg/d at least 3 days
before operation, and maintained for a minimum of
6 months with 100 mg/day aspirin.
Technical success was defined as that the lesions treated
had < 30 % residual stenosis at the end of the procedure.
Here, the technical success is not involved in the situations
of runoff vessels. Primary, assistant and secondary patency
rates were determined with the SVS (Society for Vascular
Surgery) reporting standards for dealing with lower
extremity ischemia [11]. In accordance with this standard,
primary patency rate was defined as the percentage of
patients without any re-stenosis or occlusion in the arterial
segment undergoing intervention during the follow-up
period. Assisted-primary patency rate was defined as the
percentage of patients without re-stenosis or occlusion
and patients who achieved patency via additional endo-
vascular interventions in the arterial segments suffering
re-stenosis. Secondary patency rate was defined as the
percentage of patients without re-stenosis or occlusion
and patients achieved patency utilizing additional endo-
vascular interventions in the occluded arterial segments.
Re-stenosis was defined as > 50 % luminal diameter loss
seen on angiography or duplex scanning, or 4 times ratio
of the proximal normal segment velocity.
Follow-up
Ankle brachial index (ABI), clinical examination and
ultrasound imaging were evaluated initially within 48 h
after surgery and repeated at 1, 3, 6, 9 and 12 months,
followed by testing yearly.
Statistical analysis
All data were analyzed using the Statistical Package for
the Social Sciences (SPSS) software (SPSS Inc., Chicago,
IL, USA). Continuous variables were presented as mean
± SD while categorical variables as count and percent.
Demographic and co-morbidity data were recorded for
every patient and patency data were calculated on a per
limb basis. Primary patency, assisted-primary patency
and secondary patency rates were analyzed using
Kaplan-Meier analysis with Log-rank test. Univariate
analysis with a cox proportional hazards model was per-
formed to identify risk factors for re-stenosis/occlusion.
A p-value < 0.05 was considered statistically significant.
Results
Characteristics of the patients and limb lesions
From January 2011 to March 2013, a total of 58 limbs in
53 patients underwent endovascular treatment. The mean
age of the enrolled patients was 74.2 ± 8.2 year (range,
58.0–91.0 years). Most patients were males (67.9 %).
Among the 53 patients, 32 (60.4 %) had diabetes mellitus
and 36 (67.9 %) had high blood pressure (Detailed in
Table 1). Mean lesion length were 314.8 ± 64.3 mm and all
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lesions were totally occluded before treatment. Of the 58
limbs, 30 limbs were presented with intermittent claudica-
tion, 17 were rest pain, and 11 were ulcer or minor gan-
grene. A total of 145 stents were implanted in SFA with
an average of 2.5 stents per limb. Twenty-five limbs had
only one-vessel runoff below the knee, 21 limbs had two-
vessel runoff, 10 limbs had three-vessel runoff and 2 limbs
had no-vessel runoff (Detailed in Table 1).
Immediate outcomes after intervention
The over-the-bifurcation (crossover) approach was applied
for 48 limbs (82.8 %) and retrograde approach (SAFARI
techniques were utilized through ipsilateral popliteal ar-
tery) for 10 limbs (17.2 %). No major complications like
death, cardinal infarction, acute renal failure or amputa-
tion were occurred during operations. But there were 6
(11.1 %) minor complications, including two haematomas
at the puncture site (3.7 %), one acute renal insufficiency
(1.9 %), one contrast media induced-encephalopathy
(1.9 %), and 2 anginas (3.7 %). Fortunately, all these minor
complications were cured, and no further treatment was
needed.
Outcomes during follow-up
All patients were followed up with the mean time of 12.2
± 6.1 months (range from 5 to 38 months). There were 2
patients died during the follow-up, one from cardiac in-
farction at the 7th month, and the other from cancer at
the 13th month. The baseline ABI was 0.49 ± 0.1 and in-
creased to 0.93 ± 0.2 at 1 month after intervention and
remained at 0.89 ± 0.2 at 1 year follow-up. All lifestyle-
limiting claudication symptoms transited into mild to
moderate claudication. The symptoms of rest pain oc-
curred in 16 limbs also transited into mild to moderate
claudication but one limb remained to present with rest
pain. The symptoms of gangrene transited into mild to
moderate claudication in 10 limbs and into rest pain in
1 limb.
During the follow-up period, 8 limbs experienced re-
stenosis and 4 occlusions. Ten (7 re-stenosis and 3
occlusions) occurred within 1–2 years and 2 occurred
(1 re-stenosis and 1 occlusions) within 2–3 years. The-
primary patency rates at 1, 2 and 3 years were 63 %, 12 %
and 12 %, respectively (Fig. 1a). Reintervention was per-
formed for all limbs suffering from in-stent-re-stenosis
(ISR) during the follow-up period and the vessels were
Table 1 Characteristics of the patients and lesion
Characteristics Value
Patients
Number of patients (limbs) 53 (58)
Age (years, mean ± SD) 74.2 ± 8.2
Male gender (%) 36 (67.9)
Diabetes mellitus (%) 32 (60.4)
Hypertension (%) 36 (67.9)
Coronary heart disease (%) 15 (28.3)
Hyperlipidemia (%) 19 (35.8)
Others (cerebral infarction) (%) 7 (13.2)
Lesion (all 58 limbs)
Length of lesion (mm, mean ± SD) 314.8 ± 64.3
Average number of stents per limb 2.5
Run-off vessels below the knee (0/1/2/3) 2/25/21/10
Preoperative symptoms (intermittent claudication/rest
pain/gangrene)
30/17/11
Follow-up time (months, mean ± SD) 12.2 ± 6.1
Fig. 1 Kaplan-Meier analysis of the patency rate following endovascular intervention. a primary patency, b assisted primary patency, c second patency
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successfully revascularized but 2 limbs in 2 patients. Of
these 2 patients who suffered a slight rest pain, one was
technically failed and received an oral drug medication
since this patient had no vessel runoff that surgery bypass
was unsuitable. Palliative treatment was carried out for the
other patients due to severe and life-threatening comor-
bidities. Four patients received at least 2 reinterventions
during the follow-up period and until now target lesions
still remain unobstructed. Assisted primary patency rates
at 1, 2 and 3 years were 77 %, 31 % and 31 %, respectively
(Fig. 1b). The 4 patients with occlusions underwent a
CDT (catheter directed thrombolysis) re-intervention and
subsequent PTA (percutaneous transluminal angiog-
raphy). No further stent implantation was needed. The
secondary patency rate was 93 % at 1 year, 54 % at 2 year
and still 54 % at 3 year (Fig. 1c).
During the follow-up, no major amputation was oc-
curred. Five patients (9.3 %) underwent toe dissection
due to toe gangrene and achieved a quick wound healing
after intervention.
Risk factors for re-stenosis/occlusion
Univariate analysis revealed that number of run-off
vessels was associated with re-stenosis/occlusion because
significantly higher risk of stenosis/occlusion in patients
with two run-off vessels was found compared to patients
without run-off vessel (P = 0.046). Other factors, such as
age, gender, diabetes mellitus, hypertension, hypelipidemia
and lesion length had no relationship with the occurrence
of re-stenosis or occlusion (Table 2).
Discussion
In this retrospective study, all enrolled patients were
successfully revascularized and followed. In fact, there
were still 3 patients who were not recruited in this study
because of failure of intervention. So, the real technical
success rate was 95 %. When considering that the pri-
mary goal of this study was to determine the patency
rate and durability of successful endovascular interven-
tions on TASC II D lesions, we excluded the patients
who experienced unsuccessful primary interventions
from this analysis.
The TASC II consensus reported in 2007 recommends
surgical treatment over endovascular treatment in the
case of TASC D lesions [4]. But in recent years, continu-
ous advances in endovascular techniques and facilities
have made the treatment paradigm shifted. Endovascular
techniques have been gradually used for more extensive
femoropopliteal occlusive disease and gained favorable
outcomes [12, 13]. Baril et al. reviewed the data of 79
limbs from 74 patients with TASC II D lesions treated
with subintimal angioplasty and stents. In their study,
the primary, assisted primary and secondary patency
rates at 12 months were 52.2 %, 88.4 %, 92.6 %,
respectively. Our study displayed a comparable outcome
that the primary, assisted primary and secondary patency
rates at 12 months in current study were 63 %, 77 % and
96 %, respectively. However, the satisfactory patency rate
of endovascular therapy for comprehensive lesions was
tempered by significant rates of re-stenosis and occlu-
sion. At the 24th month, the primary patency rate was
dramatically decreased to 12 % in current study, lower
than that (27.5 %) reported by Baril et al. [12]. This
implied that nearly 9/10 patients developed re-stenosis
or occlusion within 2 years after intervention. Fortu-
nately, all these lesions can be treated with endovascular
techniques and be more easily crossed along the stent
path to the distal true lumen compared to debut per-
formance. Furthermore, with close surveillance, early re-
stenosis can be easily found and re-treatment can be
performed as soon as possible that a large number of the
limbs suffering re-stenosis or occlusion can be salvaged.
Thus, the secondary patency rate at 12 months reached
up to 96 % and 63 % at 2 years in current study. Yin et al.
[13] showed more satisfactory outcomes that the second-
ary patency rate was 95 % at 2 years and maintained at
83 % at 3–4 years after intervention. In contrast, our result
was somewhat discouraging. The insufficient surveillance
time may be one reason when considering that the
surveillance time of majority patients was short, around
12 months. Though the secondary patency rate at 2 years
was not so satisfactory, no major complications occurred
during the operation and no major amputations occurred
Table 2 Predictive factors for stenosis/occlusion
Factors HR 95 % CI P value
Age 0.10 0.96–1.04 0.97
Gender 1.23 0.55–2.76 0.62
Diabetes mellitus 0.84 0.40–1.72 0.63
Hypertension 0.73 0.36–1.51 0.40
Coronary heart disease 1.25 0.59–2.69 0.56
Hyperlipidemia 0.73 0.33–1.65 0.46
Cerebral infarction 1.14 0.44–2.98 0.79
Lesion length 1.00 0.10–1.01 0.82
Number of stents 0.96 0.58–1.58 0.96
Number of Run-off vessel
(reference: 0 run-off vessel)
0.24
1 run-off vessel 0.23 0.05–1.06 0.06
2 run-off vessels 0.20 0.04–0.97 < 0.05
3 run-off vessels 0.31 0.06–1.61 0.16
Intermittent claudication 1.23 0.60–2.53 0.57
Rest pain 1.06 0.48–2.34 0.88
Gangrene 0.84 0.32–2.22 0.84
Note: only number of run-off vessels was detected as potentially predictive
factor, patients with two run-off vessel had significantly higher risk of stenosis/
occlusion compared to patients without run-off vessel (P = 0.046)
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during the follow-up time in our study. The limb salvage
was excellent. Therefore, we consider that endovascular
treatment may be the first choice treatment even in
femoropopliteal TASC II D lesions.
Besides, the preferential use of primary stenting vs se-
lective stenting during endovascular treatment for TASC
D lesions is still controversial. Some authors considered
that there was no additional benefit from primary stent-
ing while many studies have advocated the preferential
use of primary stenting for longer lesions (TASC C and
D lesions). Surowiec et al. have shown that there was no
difference in outcomes (patency or limb salvage) be-
tween patients in whom primary stenting was used com-
pared to those in whom selective stenting was used [9].
However, a previous meta-analysis compared the out-
comes of balloon angioplasty with optional stenting vs.
routine primary stenting for femoropopliteal occlusive
disease and suggested that primary stenting can be used
as a first-line endovascular treatment for symptomatic
disease in the femoropopliteal segment, mainly for long le-
sions [14]. Due to the differences in patients, producers,
analytical method among different studies, few studies can
be used to compare. Therefore, randomized clinical trials
are needed to examine whether primary stenting is super-
ior to selective stenting for type D lesions treatment.
The Outback catheter is a kind of catheter system de-
signed to allow fluoroscopically controlled re-entry of
the true arterial lumen after subintimal guidewire pas-
sage during recanalization procedures, which was safe
and effective in complicated recanalization procedures
[15–17]. But in our hospital, this device is not widely
used due to high cost. What we can utilize is retrograde
penetration and SAFARI technique. In our center, SAFARI
technique was carried out for 10 limbs and all lesions were
successfully crossed, leaving no major complications post-
operatively. Hua et al. reported SAFARI-assisted stenting
for 38 cases of long chronic total occlusion (CTO) of
TASC C and D superficial femoral lesions and no major
complications occurred as well [18]. The SAFARI tech-
nique is a safe and feasible option for patients with
infrainguinal CTO, especially TASC II D lesions.
Univariate analysis showed that number of run-off
vessels was associated with re-stenosis/occlusion, which
was in line with the previous study [19]. However,
further studies were needed for exploring whether num-
ber of run-off vessels is independent risk factors for re-
stenosis/occlusion in patients with TASC II D femoropo-
pliteal occlusive disease because multivariable analysis
was inappropriate to perform with only 12 endpoints in
this study. It should be noted that cerebrovascular disease
and hypercholesterolemia have been evidenced to be inde-
pendent predictors for re-stenosis or occlusion [12].
Besides, lesion length was also showed to be involved in
the occurrence of re-stenosis or occlusion in a recent
study [13]. But in current study these conclusions were
not confirmed. The reasons for the difference results are
unclear and further studies are needed to resolve this
issue. In addition, a previous study [20] has demonstrated
that there is a considerable risk of stent fractures after long
segment femoral artery stenting. So, in current study we
also investigated the occurrence of stent fractures consid-
ering that the objects of our study were very long SFA
lesions. Stent fractures were occurred in 5 cases and there
was no displacement and transaction. It seemed that there
was no obvious relationship between stent fracture and
restenosis since only 1 of these 5 cases showed restenosis.
This study has a number of limitations. The most im-
portant one is the limited power of the analysis due to
its retrospective nature. Moreover, this was not de-
signed as an intention-to-treat study and the primary
goal of this article was to determine whether primary
intervention could be the first choice rather than a
backup on TASC II D lesions. Thus, patients who did
not undergo successful primary interventions were
excluded from the analysis. In addition, with the limita-
tion of only 12 endpoints, multivariable analysis was
inappropriate to perform for exploring independent risk
factors in this study. Furthermore, the follow-up time is
still limited, and longer-term follow-up will be neces-
sary to determine the durability of these interventions.
Conclusion
Endovascular treatment for TASC II D lesions is safe and
can be effectively performed with acceptable hemodynamic
improvement. Though re-stenosis is very common, close
surveillance and repeated intervention can resolve this
problem.
Highlights
1. Endovascular intervention with bare nitinol stent
was performed for TASC II D lesions.
2. The secondary patency rates reached up to 96 % at
1 year after intervention and maintained at 63 % to
3 years.
3. One-runoff vessels may an independent predictor
for re-stenosis/occlusion.
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